🇺🇸 Glucagon Nasal Powder [Baqsimi] in United States

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FDA authorised Glucagon Nasal Powder [Baqsimi] on 24 July 2019

Marketing authorisation

FDA — authorised 24 July 2019

Application: NDA210134
Marketing authorisation holder: AMPHASTAR PHARMS INC
Local brand name: BAQSIMI
Indication: POWDER — NASAL
Status: approved

Read official source →

Frequently asked questions

Is Glucagon Nasal Powder [Baqsimi] approved in United States?

Yes. FDA authorised it on 24 July 2019.

Who is the marketing authorisation holder for Glucagon Nasal Powder [Baqsimi] in United States?

AMPHASTAR PHARMS INC holds the US marketing authorisation.